Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERE-110: Adeno-Associated Virus Delivery of NGF · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CERE-110: Adeno-Associated Virus Delivery of NGF | GENETIC | CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg |
Inclusion Criteria: * Alzheimer's disease as determined by NINCDS/ADRDA criteria. * Score of ≤ 4 on a modified Hachinski Ischemia Scale * Mini-Mental State Exam (MMSE) score in the range of 16 to 28, inclusive * No significant neurological or medical abnormalities contraindicating surgery, MRI/PET ...
Top 20 of 30 competitors
CERE-110 is an investigational gene therapy developed for Alzheimer's disease. It was studied in patients with mild to moderate Alzheimer's disease. CERE-110 is a gene therapy candidate that delivers nerve growth factor, or NGF, using an adeno-associated virus vector. It is not an approved treatment.
CERE-110 was developed by Sangamo Therapeutics, Inc., which trades under the ticker SGMOQ. The company sponsored the clinical development of this adeno-associated virus NGF gene therapy for Alzheimer's disease.
CERE-110 is in Phase 1 development. One Phase 1 clinical trial has been completed, and no trials are currently active. CERE-110 is investigational and has not been approved by the FDA for Alzheimer's disease or any other indication.
CERE-110 was studied in a single completed Phase 1 trial, NCT00087789, titled CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease. The trial enrolled 10 participants aged 50 years and older in the United States. It was an uncontrolled, open-label study without randomization or blinding.
CERE-110 is a gene therapy that uses an adeno-associated virus vector to deliver nerve growth factor, or NGF, to the brain. The approach is designed to provide sustained NGF expression in patients with Alzheimer's disease. CERE-110 was evaluated in a Phase 1 trial in mild to moderate Alzheimer's disease.